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Allelic loss in human cutaneous melanoma has been 
detected on chromosomes 1p, 6q, 9p, 10q, and 11q. 
Chromosome 17 contains ilnportant tUlnor suppres-
sor genes such as p53, NM23, and neurofibromatosis 
type 1 (NF1) , which have been implicated in mela-
noma tumorigenesis. The role of p53 has already been 
studied by a number of laboratories, showing con-
trasting results. In the present study, two restriction 
fragment length polymorphism (RFLP) probes for the 
NM23 and NF1 genes, together with five other RFLP 
and four variable number of tandem repeat chromo-
some 17 probes, were investigated at the loss of 
heterozygosity (LOH) level in a Southern blot-based 
assay. The NF1 gene was also tested for LOH by a 
polymerase chain reaction (PCR)-based approach in 
two different experhnents, using a dinucleotide re-
peat polymorphic probe at locus D17S250 (17q11.2-
q12), an'd an Alu probe intra genic to the NF1 gene 
(17ql1.2). A PCR single-strand conformation poly-
morphism assay was included in the study for muta-
LOSS of hete rozygosity (LOI-J) a ll ows fo r the detection of specific a reas of the hum an gcno.mc that might contain tumor suppressor genes. The technjque makes u sc of restri ction fragment length polymorphism or variable numbe r of tandem re peat (VNTR) probes in Southern 
transfer- based experiments, and polymorphic mic[osate lli te DN A 
probes in polymerase cha in rea ction (PCR)- based experim ents, 
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tion detection at the NF1-GTPase-activating pro-
tein-related domain (GRD). A total of 68 melanocytic 
tumors were analyzed. LOH was detected in 9 of 87 
informative cases (10%). LEW301 (17p11.2-pcen) pre-
sented the highest LOH frequency (22%). NM23 
showed LOH in 17% of the informative cases, while 
NFl did not show either LOH in the Southern blot-
and PCR-based experiments or mutations at the NF1-
GRD. These results are in concordance with those of 
previous smaller studies, but when conlpared with 
higher LOH frequencies obtained from other chro-
mosomes, these findings indicate that the LOH val-
ues found in our study can Inost lil(:ely be attributed 
to background effect. Thus, chromosome 17 LOH is 
likely to play an unimportant role as a genetic event 
in melanoma tumorigenesis. Nevertheless, NF1 mer-
its further study, since homozygous deletions have 
been detected at this locus in Inelanoma cell lines. 
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Human melanoma has rccen tly received considerable attention 
beca use of its rapid inc rease in inciden ce 11]. Cytogenetic studies 
havc indicated that chromosom es 1, 6, 7 , 11, and 19 are thc regions 
most fi'equently altered in mclanoma [2]. In the fo ll owin g work, we 
have conducted studies of chromosome ·17 based on the fo llowing 
rationale: (i) recently published rcsults of Andersen "I ,, / [3] suggest 
that neurofibromatosis type 1 (NFl) is involved in melanoma 
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tumorigen es is throug h inactivatio n of th e gen e o r absen ce of th e 
protein in two of e ight m e lan o ma cell lines; (ii) th e re could b e som e 
connec tio n b etween a lteratio ns of the NF 1 gen e and deve lopm en t 
of melano m a b eca u se of the cl inical resemblan ce of som e patients 
with neurofIbro matosis to patien ts w ith g ian t con genita l m e lan o-
cytic n evi (whic h ha ve an inc reased risk to r m e lan o m a); and (iii ) 
chrom osom e 17 con tains several loci linke d to can cer pre disposi-
tion (p5J, NF1, and Nl'v/23). Functio n a l in activatio n oCthe 1'53 gene 
has already been studied in o ur se ries of m e lano m as a t th e level o f 
LOH and muta tio n d etec tio n b y single- strand con fo rmatio n p o ly-
morphism (SSCP) [4J ,md immuno histoch e mistry (5) . O ur resul ts , 
based on m o lecula r techniq u es, h ave su ggested n o signi fica nt. ro le 
for the p53 gen e in th e tumo ri gen es is of m e lan o m a. in con t rast to 
other work s [6 - 8] , whi ch present th e )153 p rotein , d etected by 
immun ohi stoch e mistry, to b e associated w.ith late-stage melan o m a . 
In the presen t work we studi ed l O H o n chro m osom e 17, w ith 
special atten tio n to the NF l gene. We also expl o re d the GTPase-
activa ting protein-re la ted d o m aill of the lI e l.lro /:ibro m atos is type 1 
gene (NF1-G R.D) fo r in ac ti vating mu tatio n s, w ith o r w ith o ut 
allelic loss of th e N F 1 gen e. 
MATE R.I ALS AND METHODS 
Tissu e Spcc inlcns T lIIllOT" santplcs w ere o b taill ed fr0 l11 a tota l of 68 
melan ocy ti c lesions (35 primary melanomas, 29 metastatic melanomas, and 
4 congenital nev i). T hirt.y-fo llr (10 primar)' melanomas. 20 metasta ti c 
melanomas. and 4 congeni ta l nev i) had been treated at the Massachusetts 
Gen eral Hospi ta l. lloston. T he tlll1l0r samples in this gro up were frozen in 
liqu id nitrogen iml1led iately after surgica l removal and stored at - 70°C 
until DNA extraction. Consti tu tiona l DN A, 1;'01 1'1 20 ml of blood frOi n each 
patient, and tuntor DNA were extracrcd by phenol/chlorofo rm extraction 
and ethanol precipitation 191. Another group of 34 patients (25 pl'imary 
melanomas and 9 metastati c melanomas) were treated at the Uni ve rsi ty 
Clllli c. P3mplona, Spain . T h" tu mor mate rial was extracted from parafri n 
s3mp.lcs in this group according to prev io us protoco ls [4J. 
Chromosome 17 LOB T hirteen pairs of tumor (12 metastatic and '1 
primary melanoma) and constitutional DNA fro m patients treated at the 
Massachusetts General Hospi tal werC tested for chromosome 17 LO H using 
11 polyrnorphic-restric tion ii'agment length polymorphisnl or VNTR-
probes (Tables I, II) . T hree of these probes re late to three tum or 
suppressor genes: 1'53 (pYNZ22. 1). NF l (pHHH 202) . and NM23 (NME1). 
DNA cleavage. electrophores is. Southern transfcr, and hybrid izations were 
performed accOl'd ing to standard protoco ls 1'9]. 
Microsa teUite Assay for LOB Detection at the N F 1 Locus In o rder 
to quickJ y screen fo r LO H at the NFl locus in a large Illlltl))cr of pa tients 
wi.th highl y in fo rmative probes. we dec ided to perfo rm a PCR - based 
approach instead of using the Southc .... transfe r techniq ue with VNTR 
(microsatellite) probes, which is also va lid fo r LO H detection. T he PC R-
based Inic rosatc l1 itc assay e n ables u s to screen n o n-n al-tum o r pa irs ft) 1' LO H 
more q uickly, makes it poss ible to explore the NFl locus in tragcnicall y. and 
is more info rm;r tive than the Southern transfe r-based assay with VNTR. 
probes. Forty-s ix l11 ehlnocytic lesions (21 [i'orn the Massachusetts General 
Hospita l and 25 (i'om the University C linic, Pamplona) Were investigated 
for LO H detection at the NF'I gene: 23 primary rn"' anomas (4 fi'es h-tJ'ozen 
and 1. 9 pa raffin-embedded specimens), 1') metastatic melanomas ('1 3 fi'esh-
frozen and 6 parafrin-embedded specim ens), and 4 I'i'esh-froze l1 congeni ta l 
nevi. Two highl y in fo rmati ve microsate ll itc DNA probes were used: " 
din ucleo tide rcpe;rt polymorphism at th e 0 17S250 locus [1 0], and all Alu 
polymorphism intragcnic to the NF I gene 1111. pC R. condi tions and primer 
seq ue n ces ,~,rC re take n frO ln th e o ri g inal articles. Bric Ay, th e PCP. ... reactio n 
mixtures con tn incd 5U- ]()0 ng D NA, 70 fJ. M "aeh dNTP, 50 mM KC I, 20 
mM Tris. pH 8.4. 2 /kg/fJ.1 bovine serum albumin. 1.5 m M MgCI2 (ro r the 
D1.7S250 po lymorphism) or 1.0 mM MgCI2 (for the Alu po lymorphi sm ), 20 
pmol o f each primer, and 0.25 units Taq polymerase (Perkin Elmer-Cetus. 
Norwal k, CT) in a tota l vo lume of 1 0 fJ. 1. O ne of the primers had prev io usly 
been ·12P- labcled by the end-labeling method 19J. An automated the rmal 
cycler (MJ ll..esea rch Inc., W atertown. MA) was used to ampli fy the D N A: 
30 cycles o f denaturation (94°C, 1 min). annea ling (53 °C, 2 min ) and 
extension (72°C. 2 min) were perfor med fo r the D 17S250 po lymorphism, 
while 35 cycles of dena turation (94°C. I mi n). annea ling (52°C, I min). and 
extension (72°C. 2 min ) weI'" performed fo r thc Alu polymorph.ism . Ten 
microliters ofl oading buffe r containing 850 fJ.1 deionized fo rmam ide. 50 fJ.1 
10% xylene cyilnol, 5D fJ.1 siltur;r tcd brornopltenol bille, and 50 ,.,.1 20 X TOE 
per 011 of buti'er weI''' added to the P K products unde r the mineral oil. T he 
mixture was heitted at 95°C fo r 10 min . quickly chill ed on icc and ap plied 
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Figure 1. Loss of h e terozygosity at chromosome 17 loci in m alig -
n a nt mela nomas. A) Southern tra nsfer-based approach. B,C) PCR-based 
approach fo r LOH detection at the NFI-GR.D locus. No LOH is detected. 
A dinucleotide repeat (B) and an Alu probe (e) were used. N, normal blood 
DNA: T. tumor DNA. N lllll bers. allele sizes in kilobases. 
to a 6'10, polyacrylamide-7 M urea denaturing gel. After electrophoresis, the 
ge ls were fi xed On paper. dried at BO°C for 2 h, and exposed to x-ray fi lm 
for 24 h. 
p e R SSCP Analysis o f the NF1 Ge n e All 68 melanocyti c lesions were 
investigated fo r NF~I-G R..D mutations. We used one set of oligonucleotide 
plimers to ampli fy the NF J-G R..D by means of the pCR technique. T he 
GeneA mp PC R n .. eagcllt Kit with AmpliTaq DNA polymerase (Perkin-
Elmer-Cetns, Norwalk , CT) and an '" ltomated thermal cycler (Gene ATAQ 
Controller; Pharmac ia LKB . Uppsa la, Sweden) were used. Sequences of the 
primers and temperature condi tions fo r optimal PCR. res ults have been 
described elsewhere 1'1 2.1 . T he radioactive SSC P expel:iments wcre per-
fo rmed acco rd ing to our previo us protocol [1 3], based on the procedure of 
O ri ta cI (/ /l1 41 with minor modifications. T he nondenatu ring 6'1., polyacryl-
amide (20: 1 acrylal11idc :b is-acrylarnide) and 4.5'X, po lyacrylamide (49:1 
acrylamide:bis-acry lam ide) ge ls with '10% glycero l were rUn at either 5 or 40 
\'1./ at rOom tem perature with fa n cooling in an EC 160 DNA sequencing gel 
appara tlls (EC Apparatus Corporation, St. Petersburg. FL) . In these condi-
tio ns Inost I11l1 t<1tions- abo ut 97%-shollld be detected [1 5]. After dlyi ng 
the gels at soac fo r 2 h , they were exposed to x-ray fi lm with in tensifyi ng 
sc reen s at - 70°C between 'I and 2 d. Non radi oactive cxpc rin1 cn ts were also 
conducted in " SE 600 e lectrophoretic uni t (Hoder Scientific Instrulllents, 
San Francisco , CAl in 10% po lyacrylall1id' (49:1 acrylamide:bis- acryla mide) 
J1 0 11dc na t. uring gels w ith 10'10 g lyce ro l. at 5 W for 4 h , at 1'00111 relnpcrature, 
In this case, the DNA was visua.lizecl by cth idiUl11 b ro mide sta in ing. 
Sarcomas harboring 1'53 Illu tations [161 were ru n in parallel in the same 
polya crylan ti dc gels , as positive con trols. 
R ESULTS A N D D ISCUSS ION 
Low Freque ncy o [ Chr omosome 17 L O H in Melanoma We 
examined 13 m e lano mas fo r aUe lic loss o n chro m osom e 17 w ith 11 
po lym o rphic p ro b es. To o ur k n owled ge, this is th e largest LOH 
study of c hro m osom e 1 7 in human m elan o m a . LOH was d etected 
in 6 of13 p a tien ts (46%), and in 9 o f 87 in form ati ve loci (10'1.,) (F ig 
1; T able s I, II) . T h ese resul ts a re in agreem e n t wi th previous 
stu d ies, a ltb o u g h in m ost th e ro le of chro m osom e 17 in m elan o m a 
h as not been su ffic ie ntly studie d . T a ble III summarizes previ o u s 
re p o r ts con ce rnin g LO B fo r c hro m osom e 17. Tomlin son e/ 01 [17] 
compare d the LOH fi'cq u en cy for c h rom osom e 17 w ith three 
probes /IUS liS the LO B 0 11 chro m osom e 1 1 w ith an o the r p robe . T h e 
resul ts sh owed LOH fo r chro m osom e 1 7 in 15% of th e in form ative 
cases. LO B was fo und in 4 o f 16 info rm ative cases (25%) fo r 
pYN Z22. 1 . In addi t io n , n o LO B was de tected fo r p53 and NM23 
am o n g 10 info rmative cases. D 17S 1. D17S4, p Y N Z22.1, and 
E RB A2 loci have b een studie d by three lab o rato ries. In the first 
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Table I. Chromosom.e 17 LOR Analysis at 11 Polymorphic Loci in 13 Melanoma Patients" 
Probes 2 3 4 5 
LEWSO I ni ni 
LEWS03 LOf-! ni ni III 
" YNH37.3 I 
p144D6 I 
p YNZ22. 1 LOl-l 
LEW301 LOI-! 
LEW206 III ni ni ru 
LEW207 LOJ-( ni 
I' HHH202 111 ni 
NME I ni IlJ III III 
pTJ-(H59 LOJ-( 
II LOH , loss of hete rozygosity; I ~ i ! llollin formi1ti vc; I, in formative; _, nor determined. 
study, the D17S1 locus (17p1 3) showed no LOH in two informa-
tive cases out of eight melanoma s [1 8]. Nordenskj61d el al [19] 
observed LOH in one of eigh t informative c ases (12'%), but the 
authors did not specify whether the loss corresponded to one or 
both of th e two probes (D17S1 and D17S4). Finall y, Millikin ef "I 
[20] studi ed chromosom e 6 for alleli c loss in m elanoma, including 
o ne additional probe fo r chromosomes lp, 11q, l6q , and 17p 
(pYNZ22.1). Among 17 cases tested , LO J-I was detected in one of 
seven informative loci (14%). 
Our study has anal yzed chromosome 17 for LOH w ith 11 
po lymorphic probes, with a special refer ence to the NFl gene. The 
LOH fi·equ ency was almost equally distributed over both arms of 
chro m osome 17: 9% fo r 17p, and 12'10 on 17q. On 17p, LOJ-I was 
detected in the 17pter-p12 region in 2 of 12 in fonmltive cases 
(17%); at 17p13.3, in one of 33 in fo nnative cases (3'V,, ); and at 
17pl1 .2- cen in two of nine informative cases (22'Yc, ). On 17q, LOH 
was detccted at 17pccn-q1 2 in one o f 12 informative cases (8%); at 
17q11.2-q1 2 in no cases; at 17q22 in 17% of the cases, and at 
17q23- q25. 3 in 18% of cases. T hus, the 17p perice ntromeri c region 
was thc m ost fi-cquen t ly deleted part of chromosome 17, fo ll owcd 
b y 17q23-q25.3, the 17p telol11eric region , and the region of th e 
NM23 genc o n 17q22. These values of LOH are not sign ificant 
compared w ith o the r studies w ith repo rted fi·eg uencies of LOH of 
3 1% o n Ip [21], 40% on 6q [20], 60% and 77°/" on 9p [22 ,23] , 52% 
o n 1 Oq [24], and 67'Y;, on 'II q 117]. Consequently LOH va lu es of9'y(, 
Patiellts 
(j 7 8 9 10 11 12 13 
ni ni ni ni LOH 






ni ni ni 
111 111 III 
111 LOH 111 
ni LOH 
(17p) and 12% (17q) found in the present study can m ost likely be 
attribu ted to background effect. 
Absence of LOR at the NFl Locus and Point Mutations at 
the NF1-GRD in Melanoma The analysis of th e D17S250 
polymorphism failed to de tect LOH in any of the 31 (14 fresh-
frozen and 17 paraffin-embedded specimens) informative cases 
among 46 analyzed (Fig 1). In order to increase the number of 
informative patients, the 15 homozygous cases were subjected to a 
second PCR-based assay with an AJu polymorphism. This marker is 
within the NFl locus at 17q11.2, and is useful for diagnosis of type 
1 ne urofibromatosis . Seven of the 15 tumors were infomlative, but 
none showed LOH (Fig 1); four other tumors w ere hom ozygous 
for the constitutiona l DNA, and the remaining four tumors did no t 
y ield evaluable data . T he PCR SSCP study also eventuated in a 
negative resu lt (Fig 2): none of the 68 tumors showed a SSCP 
mobility shift in the polyacrylamide gels. Since mutations are 
d etected in SSCP analysis by a change in the mobility of single 
strands, we performed the SSCP experiments under different 
conditions with 6% polyacrylamide (20: 1 acrylamide:bis-acryl-
amide), 4.5'Yc, pol yacrylamide (49:1 acrylamide: bis-acrylamide), and 
J 0°;:, polyacrylamide (49 :1 acrylamide :bis-acrylamide), in order to 
avoid f.1.lse negative results. 
The role of the NF1 gene in melanom a tumorigenesis has 
recentl y been explored by Andersen ef al [3] . Southem blot an alysis 
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'17p .l1 .2-pccn 
17pccn- '11 2 
17pcen-'11 2 
17'1 11 ,2-'112 
'17'122 
17'123-'125 ,3 
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Table Ill. Summary of Studies Investigating the Frequency of LOH on Chromosome 17 in Melanoma 
R.eference 
Tomlinson el al. 1993 
Orita el nl. 1989 .. 
Nordenskj61d el nl. 1990 
Millikin el al. 1991 
Current study 













No. of Loci Displayed" In formarive Loci No. of Loci with LOH 
48 26 4 
16 4 0 
Il. S." 8 1 
17 7 I 
121 87 9 
II This number is c'llclIla[cd hy addi tl g dl l! \Iumher of cases for whil: h c;lch prohe shows homozygosity or heterozygosity ill the cOllsti tuti o l1:l1 DNA. 
' pYNZ22.1 ( 171' 13.3) . TP53 ( 171'1.1.1). and NM23 ( 17q2 2) 
' 0 17S I (171'1 3). and EIU1A2 ( 17q25) 
: D17S I (171'13) . and D I7S4 ( 17q23-q2S.3) 
n .s., l1 0t show1I . 
f pYNZ22. 1 ( 171''13 .3) 
was performed usin g six NF'I cD NA clones, a Nolf linking clone, 
an d marker pHHH202 estim ated to be 0.6 cM centromeric co the 
F1 gene. T hese autho rs detected a bo m ozygous de letio n of NF I 
in o ne of eigh t melanoma cell lin es, resul ting in a loss of detectable 
mRNA and protein , as well as the apparent absence of prote in and 
mR-NA in another m e lanoma. 
The present study analyzed LOH in 46 melanocytic tumo rs w ith 
a highly in fo rma tive PCR-based approach using a dinucleotide 
repeat po lym o rphism, and an Alu polymorphism, intragenic to 
NF1 . pHHH 2U2 was also used to test LOH in nine melanomas by 
Sou thern blot analys is. We did n ot limi t o lll' investigation to all e li c 
loss detection. Mutation screen ing at the NF/-GRD locus was 
conducted w ith 68 melanocytic tumors. 
O ur negative res ul t in this large series of m elanocytic tum ors 
contradicts the results of Andersen Ci 01 r3]. It must be acknowl-
edged th at the discovery of hom ozygous deletions has been use ful 
in proposing new tumor suppressor genes at particul ar loci o n 
different chro m oso mes. When tumor cell lines are studied, how-
ever, onc must always keep in mind th at seconda1,)' chromosomal 
alterations are com m on ly o bserved as artifacts. For example, region 
9p21 has been freq uentl y invo lved in de letions and rea rrangements 
in dysplastic nevi [25]. Similarly, the 1'16 (MT'S'J) gene, p robably a 
tumor suppressor, has been impli cated in the genesis of vario us 
tumors, incl uding fam ili al melanoma [26]. T h ese two loci have 
been mutated w ith som e freq uency when m e lan om a cell lines ha ve 
been ana lyzed. but a lower fi'equency of mu tation has been 
demonstrated in the }J 16 gene w hcn tumors , rather than cell lines. 
a re studied [27]. This phenomeno n m ay explain the findings of 
A nderssen cf 01 [3] , altho ugh they have maintained tha t secondary 
C 1 2 3 4 5 6 7 8 9 10 C12345678910 123456789 
B c 
A 
Figure 2. Mutation screening at the NF1-GRD by PCR SSCP 
a.nalysis in cutaneous melanoma, No mobi li ty shifts (I11Ul'ations) arc 
detected. DifFe rent electrophoretic conditions were explored. A) Autora-
diography of a 4.5'% polyacrylamide (49: '1 acrylal11ide:bis-acrylal11ide) ge l 
containing 1 OtXI g lycerol . run at 40 W for 8 h . at 1'00111 tCI11pe r <ltu rc. under 
fa n venti lation. il) Autoradiography of a 6% polyacrylamide (20 : I acryl-
amide:bis-acrylalllidc) gel conta ining I (J oy., glyce rol. rlln at 4(J W for 8 h. at 
roo n1 tenlpcratu rc under ta ll vClltiJ atio ll. C ) Ethid illlll broln idc stained 101X, 
pol yacrylamide (49:1 acrylaI11ide:/lis-acrylamide) gci containing 10'1., glyc-
ero l, rll n at 5 W fo r 4 h. at r 00l11 tcrnpcratuJ"c. in a , vater rcfiigc rn tcd 
electrophoretic chamber. c. corresponds to the nondenatured DNA colltrol 
(i.e., where the doublc-srranded DNA migrates). 
changes have n ot been detected o n chro m osom e 17 from cul tured 
m elanoma cell lines [28]. 
Another explanation is that th e timing of the deve lopm ent of the 
genetic les ions in m elanoma might be criti ca l, and th us th e resu lts 
of A nderssen ci 01 [3] and our findings might be complem en tary. 
The protein fun ction cou ld be lost initia lly by mechanisms other 
than LOH o r point mutatio ns. In any case, additional studi es on e ll 
lincs and the tumors fi 'om which the cell lines are derived, with a 
combination of techniqu es such as mRNA and p rotein detection, 
highly polymorphic microsatellite DNA probes for LOI-! detection , 
and mutation screenings for th e NF1 locus are n eeded to establish 
more definitive ly w hether NFl is involved in melanoma tum01;-
gen esis. 
For example . th e role of NFt in human tumors othe r than 
m e lanoma h as also been investigated. Cawthon CI 01 P9] detected 
NF 1 mutations in 6 of 72 NF l patien ts. In it similar filsh ion, 
Upadhyaya ef 01 [30] anal yzed exons 1 to 9 of NF I (20% of the tota l 
length) in more than 200 NFl patients and recorded a total of fou.r 
mu tations, in exons 2 and 4 . L i el 0/[1 2]. however. were the first to 
demonstrate that three sporadic condition s- colon adenocarci-
noma. m yelodysp lastic syndrome, and anaplastic astrocytoma-
contained the sam e mu tation at codon -1423. in th e NF1 -GRD . 
Desp ite our negative findings vis-a-vis FI-GRD. we cannot 
excl udc the poss ibili ty that m elanomas might be mutated in other 
exons of tbe NFl gene, outs ide of the GR.D [30], or even in in trons 
[3 1]. 
Apart fi'om melanomas, othe r ne ural crest-derived tumors show 
NFl alterations . For exampl e , allelic losses of the NFl gcne h ave 
been detected in a i\lF1-deri ved neurofibrosarcoma [32]. N el1l'ofi-
bro min express ion has also been reported to be dec reased in 4 of 10 
neurob lastoma cell lines w ith two of these lin es showing NFl 
muta tion s [33 J. In contrast, 76 neuroblastomas did not ex hibi t an y 
l11utation afte r PC R SSCP screenin g for NF1-GR.D under the sam e 
techni cal condi tio ns in two independen t laborat01; es [34.35] . 
Based o n our ana lysis ofa large number of tum ors. it appea rs that 
LOH for chromosome 17 is re lative ly uncommon 111 cutaneo us 
m clanoma. Nonethel ess, furthe r studies are needed to clarify the 
role of NFl in mel ano m 3 tumo rigenesis . 
The mllh"rs ff' ish If I Ihnffk A ff(Off ill Fcnlliffdez.fi'r Ihe I'h(} ro.~ rn/'hir work ntld fl1arin 
ill' /a Pa:: Lm,sn )1 Laugn for Itt·,. J. .. illd assistance 1II;(h 'he: lilJrfll'y 1'('.'\OIll"(('S. This 
n'sf'nrrh ff'ns ji fffdcri iff /,(/1'1 1/ )' n .~rn ffl fro Iff rlf(' iHnssndfffsef(s GCfff'ml HO-'I'ilnl-
H nmard C ffr nffellffS ilialo.!:), R ... <I·(/I'Ch Cml('/' ntld FISS Grmll 9210783, fl l ndrid, 
SJJfl i/l.J. S. Casfn:srlllfl Il'as aId/ofl!(?I tl1c DCI'(lr' III (,IIf (~fE(I"rnlio", U lli ll('/'sirit's (Jud 
Rf'.'carch '!f Ihe Bnsq ffe G(l I' ert ffff erll, Viloria, Spn iff ; Renl C() /f :~ i" COfff l'l ffl rff.«' eff 
Hnr"nn/ , Bos/olI , 1\11'1; allfi P",ulnc;()1/ CicJII (jlr(l de /n A.H,rintio" Espniio/a Cn1lfrn 
cI COffea, Madrid, Sl'n iff . M .-P. Rffbi,) reai lled ji l/ld" ./i'(ll/l Ihe G"J'crt//iW/I( (If 
I, TilIJr1n·" , Pnlllp /()IIfJ , Spa;,, _ 
I ff //l emor;/l m: this article is dedicated to thc mel110ry of J.J. Vazquez. MD. 
PhD. coauthor of this work. emillellt pathologist. and above all fricl1 d. who 
tragic,"ly died ill his loved moul1tains ill Northern Spain. 
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